FDA accelerated-approval reform is changing oncology evidence requirements

Reading the signal

The FDA accelerated-approval pathway has historically allowed approval of oncology programs on the basis of an intermediate or surrogate endpoint that is "reasonably likely to predict" clinical benefit, with confirmatory evidence required post-approval. The Aduhelm episode and the FDORA reform that followed have altered the operational expectations on what sponsors deliver alongside an accelerated decision.

Three changes are now landing in oncology programs:

• Confirmatory trials are expected to be enrolling, often substantially enrolled, at the time of the accelerated decision. The "we will start the confirmatory trial after approval" frame that some sponsors used historically is no longer well-supported by the agency.
• Surrogate endpoint validity is being interrogated more rigorously. The clinical literature on the surrogate-endpoint-to-overall-survival relationship in a given indication is now part of the conversation in pre-submission meetings.
• The withdrawal pathway for accelerated approvals where confirmatory benefit is not demonstrated has been used more visibly in the past three years. The political and reputational frame around accelerated approval has shifted.

Commercial implications

For sponsors of oncology assets approaching accelerated submission:

1. Time-to-confirmatory-readout is now part of the commercial plan, not a post-approval afterthought. The launch shape and the confirmatory readout are being viewed by the field as one continuous commercial event.
2. The accelerated label is more contingent than it was. Pricing and contracting strategies that relied on label durability through to the confirmatory readout need a contingency layer.
3. The pathway is still preferable to standard approval for many oncology indications. The reform changes how sponsors prepare, not whether the pathway is used.

What we are watching

• The rate of accelerated approvals in oncology over the next twelve months and any visible shift in indication mix.
• Confirmatory withdrawal events and the FDA framing around them as the agency clarifies the durability question.
• Sponsor pre-submission strategy adjustments, particularly around when confirmatory trial enrolment begins relative to the accelerated submission timing.